Canaan X

Quantum Circuits, Inc. specializes in the development and manufacture of quantum computers utilizing superconducting devices. Founded in 2015 and located in New Haven, Connecticut, the company aims to innovate in the field of quantum computing by delivering full-stack systems that efficiently scale. Led by Dr. Robert Schoelkopf, a prominent figure in quantum science, Quantum Circuits employs a unique dual-rail quantum qubit design that incorporates built-in hardware error detection and conversion. This approach allows for a highly scalable error-corrected system, requiring significantly fewer physical qubits per logical qubit and providing a more efficient pathway to fault-tolerant quantum computing. By focusing on solid-state quantum bits, the company enables clients to perform error-free computations, thereby accelerating research and advancing the practical applications of quantum technology.

Normunity is a biotechnology company focused on developing precision immuno-oncology medicines, specifically a new class known as immune normalizers. These medicines aim to target novel mechanisms that enhance the body’s natural immune response against cancer. In collaboration with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is researching newly-discovered mechanisms of immune disruption in cancer, utilizing proprietary discovery platforms to explore the intricate interactions between cancer and the immune system. The company is advancing a pipeline of immune normalizers, which includes initial drug programs designed to address the exclusion of T-cells from immune-sensitive tumors and other factors that impede normal immune function in cancer. Normunity operates from locations in Boston, Massachusetts, and West Haven, Connecticut.

Rallybio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with severe and rare disorders. Founded in 2018 and based in New Haven, Connecticut, the company is advancing its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition that can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's portfolio includes a range of promising product candidates targeting rare diseases across various therapeutic areas, including hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. The company's efforts are supported by a team of experienced professionals with extensive expertise in biopharma research and development.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Quantum Circuits, Inc. specializes in the development and manufacture of quantum computers utilizing superconducting devices. Founded in 2015 and located in New Haven, Connecticut, the company aims to innovate in the field of quantum computing by delivering full-stack systems that efficiently scale. Led by Dr. Robert Schoelkopf, a prominent figure in quantum science, Quantum Circuits employs a unique dual-rail quantum qubit design that incorporates built-in hardware error detection and conversion. This approach allows for a highly scalable error-corrected system, requiring significantly fewer physical qubits per logical qubit and providing a more efficient pathway to fault-tolerant quantum computing. By focusing on solid-state quantum bits, the company enables clients to perform error-free computations, thereby accelerating research and advancing the practical applications of quantum technology.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Spine Wave, Inc. is a manufacturer of medical devices focused on the treatment of spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company develops and markets a range of innovative products aimed at providing surgical solutions for spine surgeons and their patients. Its offerings include expandable PEEK spacers, interbody devices for posterior surgery, pivoting and lateral spacer systems, and the GraftMag Graft Delivery System for bone graft delivery. Additionally, Spine Wave produces fixation products designed for addressing degeneration, deformity, tumors, and trauma in the thoracolumbar spine, as well as anterior cervical plate systems for spinal fusion from C2-C7 and cervical spacer systems for degenerative disc disease from C2-T1. The company distributes its products through a network of distributors, emphasizing a surgeon-driven approach to product development to address real surgical challenges.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.

Spine Wave, Inc. is a manufacturer of medical devices focused on the treatment of spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company develops and markets a range of innovative products aimed at providing surgical solutions for spine surgeons and their patients. Its offerings include expandable PEEK spacers, interbody devices for posterior surgery, pivoting and lateral spacer systems, and the GraftMag Graft Delivery System for bone graft delivery. Additionally, Spine Wave produces fixation products designed for addressing degeneration, deformity, tumors, and trauma in the thoracolumbar spine, as well as anterior cervical plate systems for spinal fusion from C2-C7 and cervical spacer systems for degenerative disc disease from C2-T1. The company distributes its products through a network of distributors, emphasizing a surgeon-driven approach to product development to address real surgical challenges.

Spine Wave, Inc. is a manufacturer of medical devices focused on the treatment of spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company develops and markets a range of innovative products aimed at providing surgical solutions for spine surgeons and their patients. Its offerings include expandable PEEK spacers, interbody devices for posterior surgery, pivoting and lateral spacer systems, and the GraftMag Graft Delivery System for bone graft delivery. Additionally, Spine Wave produces fixation products designed for addressing degeneration, deformity, tumors, and trauma in the thoracolumbar spine, as well as anterior cervical plate systems for spinal fusion from C2-C7 and cervical spacer systems for degenerative disc disease from C2-T1. The company distributes its products through a network of distributors, emphasizing a surgeon-driven approach to product development to address real surgical challenges.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.

Spine Wave, Inc. is a manufacturer of medical devices focused on the treatment of spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company develops and markets a range of innovative products aimed at providing surgical solutions for spine surgeons and their patients. Its offerings include expandable PEEK spacers, interbody devices for posterior surgery, pivoting and lateral spacer systems, and the GraftMag Graft Delivery System for bone graft delivery. Additionally, Spine Wave produces fixation products designed for addressing degeneration, deformity, tumors, and trauma in the thoracolumbar spine, as well as anterior cervical plate systems for spinal fusion from C2-C7 and cervical spacer systems for degenerative disc disease from C2-T1. The company distributes its products through a network of distributors, emphasizing a surgeon-driven approach to product development to address real surgical challenges.

Tallan is a Hartford, Connecticut-based provider of customized technology services with over 30 years of experience in custom application development and data management. The company specializes in delivering innovative solutions that enhance operational efficiency, reduce costs, improve customer experiences, and drive revenue growth. Tallan's expertise encompasses a range of areas, including software development, infrastructure architecture, business intelligence, mobile platforms, user experience, and eCommerce. Additionally, the company offers a unique bug and defect database known as Bug Appliance, which helps manage issues in software development projects. Recognized as one of the select Microsoft National Solution Providers, Tallan has achieved multiple Gold Competencies in Microsoft technologies, underscoring its commitment to quality and technical excellence.